Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have seen revenue climb in recent years thanks to their expertise in one particular area: weight loss drugs. The companies are leaders in this market that analysts expect to reach nearly $100 billion by 2030. Today, they each sell injectable drugs, though Novo recently scored the first-ever approval for an oral drug of this particular class. And Lilly's oral candidate, under regulatory review right now, may be next.The companies make GLP-1 drugs, products that interact with hormonal pathways involved in the digestion process -- and these types of drugs have proven their popularity worldwide, with demand even surpassing supply at certain points.So now, with the era of weight loss pills about to start, it's a great time to take a closer look at each of these pharma giants. Which company will dominate the weight loss drug market in 2026? Let's find out.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool